Business Wire

YAMAHA MOTOR: Consolidated Business Results Summary — Fiscal Year 2020 Ending December 31 —

Share

Yamaha Motor Co., Ltd. (TOKYO:7272) announces consolidated business results for the full fiscal year. Net sales were 1,471.3 billion yen (a decrease of 193.5 billion yen, or 11.6% compared with the previous fiscal year). Operating income was 81.7 billion yen (a decrease of 33.7 billion yen, or 29.2%), ordinary income was 87.7 billion yen (a decrease of 31.8 billion yen, or 26.6%), and net income attributable to owners of parent was 53.1 billion yen (a decrease of 22.7 billion yen, or 29.9%) . We were able to partly recover from the negative effects of the COVID-19 pandemic in the first half with net sales results in the fourth quarter (October -December) at 404.2 billion yen (an increase of 6.7 billion yen, or 1.7% on the same period over the previous fiscal year), and operating income was 25.3 billion yen (an increase of 9.9 billion yen, or 64.5%). For the fiscal year, the U.S. dollar was traded at 107 yen (an appreciation of 2 yen against the previous fiscal year), and the euro at 122 yen (no change from the previous term).

For net sales, although sales increases in the Robotics and Financial Services Businesses were achieved, the Motorcycles and Marine Products Businesses within the Land Mobility Business saw decreases in sales volumes due to the effects from the COVID-19 pandemic, which resulted in a decline in sales overall. Operating income declined overall due to factors such as the impact of foreign exchange rates and decreases in operation rates due to the temporary closures of factory operations in each country.

Forecast of Consolidated Business Results for the next fiscal year ending December 31, 2021

Net Sales

:

1,700.0 billion yen

Operating Income

:

110.0 billion yen

Ordinary Income

:

110.0 billion yen

Net Income Attributable to Owners of Parent

:

72.0 billion yen

About Yamaha Motor Co., Ltd.

Yamaha Motor (TOKYO: 7272) is a world-leading enterprise manufacturing land-mobility such as motorcycles, all-terrain vehicles, and electrically power assisted bicycles, marine products such as boats and outboard motors, robotics products such as surface mounters and drones, as well as engagement in the finance business. The company’s diverse businesses and wide variety of products are built around its proprietary technologies focused on powertrain, chassis and hull, electronic control, and manufacturing technologies. Yamaha Motor operates global development, production and sales networks through 140 subsidiaries and equity-method affiliates in 30 countries and regions, working to realize our Corporate Mission of being a “Kando* Creating Company.” About 90% of consolidated net sales are generated in more than 180 countries and regions outside of Japan. Please visit http://global.yamaha-motor.com.

Contact information

Naoto Horie
Corporate Communication Division
Global PR Team
Yamaha Motor Co., Ltd.
TEL: +81(0)3-5220-7211
ymcglobalpr@yamaha-motor.co.jp

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Mobidiag sai CE-IVD-merkinnän korona-, influenssa A-, influenssa B- ja RS-viruksen tunnistavalle Amplidiag® RESP-4 -testilleen1.3.2021 09:00:00 EETTiedote

Mobidiag Oy on saanut CE-IVD-merkinnän Amplidiag® RESP-4-molekyylidiagnostiikkatestilleen, jolla pystytään nopeasti tunnistamaan yhdellä kertaa yleisimmät hengitystieinfektioita aiheuttavat virukset SARS-CoV-2 (koronavirus), influenssa A, influenssa B ja RSV. Kyseiset virukset aiheuttavat samankaltaisia oireita, joten lääkäreiden ei ole helppo päätellä, mikä virus potilaalla on. Amplidiag® RESP-4 -testillä virus pystytään määrittämään nopeasti ja luotettavasti yhdestä nenänielunäytteestä, mikä helpottaa oikean hoitopäätöksen tekemistä. Testi tehdään Mobidiagin Amplidiag® Easy -laitteistolla, jonka etuja ovat optimoitu näyteseulontaprosessi sekä automaattinen DNA/RNA:n eristys ja PCR-levyn valmistelu. Laitteisto perustuu vakiintuneeseen korkean suorituskyvyn PCR-tekniikkaan ja pystyy käsittelemään 46 näytettä noin kolmessa tunnissa. Uusi testi laajentaa entisestään Mobidiagin diagnostiikkatestivalikoimaa. Mobidiagin toimitusjohtaja Tuomas Tenkanen: ”Olemme erittäin tyytyväisiä saatuamme

CLH Evolves to Exolum, the Company’s New Global Brand1.3.2021 08:00:00 EETPress release

Exolum is the new brand name chosen by the CLH Group from now on to face its ambitious objectives for the future, focused on adapting its business to decarbonisation and the energy transition, the digitalisation of its activities and the fight against climate change. This rebranding is due to the need to adapt to the new environment and to transform the company itself which, in addition to carrying out oil product storage and transport activities in Spain, has embarked on an international growth process and is now present in 7 other countries. The group has expanded its activity to the storage, management and transportation of liquid products, especially chemical products, operating in new sectors, such as eco-fuels, the circular economy and the development of new energy vectors. The new name, simple but modern, shows a spirit where innovation is the key. The Exolum brand was originally devised as the CLH Group subsidiary dedicated to entrepreneurship and innovation. However, after sev

CGTN: What Are Generations of Chinese Communists Striving For?27.2.2021 18:36:00 EETPress release

The Communist Party of China (CPC), the ruling party of the world's most populous nation and the second largest economy, is turning 100 this year. What has been motivating the CPC to fight against one challenge after another over the past century? This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210227005021/en/ "The original aspiration and the mission of Chinese Communists is to seek happiness for the Chinese people and rejuvenation for the Chinese nation," General Secretary Xi Jinping of the CPC Central Committee said in his report to the 19th CPC National Congress in October 2017. "This founding aspiration, this mission, is what inspires the Chinese Communists to advance," Xi said. Self-discipline, selflessness In March 2018, Xi, also the Chinese president, further explained the cause pursued by the CPC with a quote from an ancient poem: "A virtuous person is as sharp-sighted as a clear mirror hanging high, a selfless perso

Colicity Inc. Announces Closing of $345 Million Initial Public Offering27.2.2021 01:00:00 EETPress release

Colicity Inc. (the “Company”) announced the closing today of its initial public offering of 34,500,000 units, including the underwriters’ exercise of their full over-allotment option for 4,500,000 units, at a price of $10.00 per unit. The units are listed on the NASDAQ Stock Market (NASDAQ) and began trading under the ticker symbol “COLIU” on February 24, 2021. Each unit consists of one Class A share and one-fifth of one redeemable warrant, with each whole warrant exercisable to purchase one Class A share at a price of $11.50 per share. Only whole warrants will be exercisable. Once the securities comprising the units begin separate trading, the Class A shares and warrants are expected to be listed on the NASDAQ under the symbols “COLI” and “COLIW,” respectively. Colicity Inc. is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company int

C3 AI and Baker Hughes to Provide Enterprise AI Solutions to Accelerate PETRONAS Digital Transformation Program26.2.2021 17:00:00 EETPress release

C3 AI (NYSE: AI) and Baker Hughes today announced an artificial intelligence (AI) collaboration with PETRONAS, a global energy and solutions company from Malaysia, to apply BakerHughesC3.ai (BHC3) technology across PETRONAS’s strategic digital transformation programs. As the custodian of Malaysia's national oil and gas resources, PETRONAS runs an extensive digital transformation program across energy operations to extract value from data. The adoption of AI as part of its overall program for improved oil and gas productivity, asset integrity, and safety supports PETRONAS’s commitment to provide clean, efficient energy solutions by harnessing the power of technology. PETRONAS will work with energy technology, data science, and AI experts at Baker Hughes and C3 AI to collaborate on projects focused on improved reliability of energy assets in critical operations. Utilizing Microsoft Azure, PETRONAS will deploy the BHC3™ Reliability application to further improve maintenance programs for g

Avania in Position for Next Stage of Growth26.2.2021 16:00:00 EETPress release

Avania, a leading global full-service contract research organization (CRO) focused on medical technology (MedTech) development, today announced that it has successfully refinanced its existing banking facilities with Crescent Capital Group. “This new banking facility allows us to accelerate our next phase of organic and acquisitive growth over the next few years,” said Edo van Houten, CFO of Avania. “This transaction is also a reflection of the progress we have made in our brand strategy and position in the market, and it demonstrates the confidence of the financial community in our operational and strategic plan.” Avania has navigated confidently through the COVID-19 pandemic, posting a strong year of growth in 2020 despite the pandemic. The company will continue its growth trajectory as a global MedTech-focused CRO, supporting products from concept through post-market support. MedTech is all Avania does, navigating innovative medical technologies to market effectively and efficiently

Ipsen Receives Positive CHMP Opinion Recommending Cabometyx® in Combination With Opdivo® as First-line Treatment for Patients Living With Advanced Renal Cell Carcinoma26.2.2021 14:37:00 EETPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval for Cabometyx® (cabozantinib) in combination with Bristol Myers Squibb’s Opdivo® (nivolumab) for the first-line treatment of advanced renal cell carcinoma (aRCC). The European Commission, which has the authority to approve medicines for the European Union (E.U.), will now review the CHMP recommendation and a final decision on the application in the E.U. is expected in the coming months. “Advanced renal cell carcinoma is a disease that significantly impacts the lives of people around the world. We’re proud to be able to share that the CHMP has confirmed a positive recommendation for Cabometyx® in combination with Opdivo®, bringing this impactful new treatment option one step closer for patients,” said Howard Mayer, Executive Vice President and Head of Research and Development, Ipsen. “At Ipsen, w

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom